# Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years

> **NCT01073462** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 67 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- Chronic Kidney Disease Stage V
- Cardiac Morbidity

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01073462
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2014-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01073462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01073462, "Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01073462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*